Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Ekso names Bionic P&O as first Ekso Indego Personal distributor within the orthotics and prosthetics industry

Ekso Bionics Holdings (NASDAQ:EKSO) announced it has selected Bionic Prosthetics & Orthotics Group (Bionic P&O) as a non-exclusive distributor of its Ekso Indego Personal device—the alliance marking Ekso’s first...

April 23, 2025

Developments

FDA clears Aclaris’ IND application for ATI-052 trial

Aclaris Therapeutics (NASDAQ:ACRS) announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 1a/1b trial of ATI-052—expected to launch in Q2 of this year. According to Aclaris, the...

April 22, 2025

Developments

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

Atossa Therapeutics (NASDAQ:ATOS) announced that the USPTO has granted a new patent for enteric oral formulations comprising (Z)-endoxifen, including methods of treating patients. According to Atossa, the patent...

April 22, 2025

Developments

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Closely held PharmaJet announced it will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems at the World Vaccine Congress (WVC) on April 23, 2025 at 12:25 pm ET...

April 17, 2025

Developments

eGenesis and OrganOx report FDA clearance of IND application for ACLF treatment

Closely held eGenesis and OrganOx announced that the FDA has cleared the IND application for EGEN-5784—a human-compatible, genetically engineered porcine liver—designed for use in combination with the OrganOx...

April 15, 2025

Developments

Ironwood reports updates on apraglutide following FDA interaction

Ironwood Pharmaceuticals (NASDAQ:IRWD) announced that a confirmatory Phase 3 trial evaluating apraglutide in short bowel syndrome with intestinal failure (SBS-IF) and dependence on parenteral support, is a requirement...

April 14, 2025

Developments

Mayo study validates Aditxt’s ADI-100 induces immune tolerance to GAD

Aditxt (NASDAQ:ADTX) announced that a Mayo Clinic study has confirmed ADI-100 induces immune tolerance to glutamic acid decarboxylase (GAD)—a key autoantigen connected to multiple autoimmune conditions including Type 1...

April 14, 2025

Developments

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced the initiation of its first U.S.-based Phase 1/2a trial of CMND-100 in alcohol use disorder (AUD) at the Johns Hopkins University School of Medicine. According to...

April 11, 2025

Developments

Chamath Palihapitiya Discusses Perimeter Medical’s AI-Driven Cancer Margin Imaging on Flagrant Podcast

During a recent episode of the Flagrant podcast hosted by Andrew Schulz and Akash Singh, investor and entrepreneur Chamath Palihapitiya offered a compelling example of how medical innovation can drive meaningful...

April 10, 2025

Developments

ARPA-H grants Ginkgo and partners $29M to advance distributed manufacturing of medicines using grain

Ginkgo Bioworks (NYSE:DNA) announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H) and partners—Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by...

April 10, 2025

Developments

FDA grants three FTDs for Allogene’s ALLO-329

Allogene Therapeutics (NASDAQ:ALLO) announced that the FDA has granted three fast track designations (FTDs) for its ALLO-329, a next-generation dual-target CD19/CD70 allogeneic CAR T for the treatment of lupus...

April 8, 2025

Developments

TrillaMed and Profound partner to bring TULSA-PRO to Veterans and service members

Profound Medical (NASDAQ:PROF; TSX:PRN) and TrillaMed, a Service-Disabled Veteran-Owned Business (SDVOSB), have announced a partnership to support the federal deployment of TULSA-PRO—the MRI-guided, incision-free...

April 4, 2025

Developments

AC Immune reveals positive Phase 2 data from trial in early PD

AC Immune (NASDAQ:ACIU) announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn trial evaluating ACI-7104.056—its anti-alpha-synuclein (a-syn) active immunotherapy candidate—for the...

April 3, 2025

Developments

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Kazia Therapeutics (NASDAQ:KZIA) announced it will receive $1 million for the sale of all intellectual property (IP) and trademark rights of Cantrixil to Vivesto (Nasdaq Stockholm:VIVE). Vivesto licensed the exclusive...

March 31, 2025

Developments

Neural shares commence trading on Frankfurt Stock Exchange

Neural Therapeutics (CSE:NURL) announced that shares of the company have commenced trading on the Frankfurt Stock Exchange under symbol “M6B”. The company is developing therapeutics to address mental illnesses related...

March 31, 2025

Developments

Leap reports positive Phase 2 data of sirexatamab in MSS CRC

Leap Therapeutics (NASDAQ:LPTX) announced positive updated data from its Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy, compared to bevacizumab...

March 26, 2025

Developments

Coya reports progress of first-in-class Treg-derived exosome program

Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic...

March 26, 2025

Developments

Sunshine enters agreement to market generic antibiotics in Canada

Sunshine Biopharma (NASDAQ:SBFM) announced that it has signed an agreement to market two new generic antibiotics in Canada through its wholly owned Canadian subsidiary, Nora Pharma, subject to regulatory approval...

March 25, 2025

Developments

Oncotelic completes Phase 1 study of OT-101 and IL-2 in metastatic solid tumors

Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors. According to Oncotelic, this announcement coincides with a...

March 25, 2025

Developments

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis

Can-Fite BioPharma (NYSE American:CANF) announced that it has initiated a pivotal Phase 3 study of its oral drug Piclidenoson for the treatment of psoriasis, with FDA- and EMA-approved protocol. According to Can-Fite...

March 24, 2025

Developments

First patients recruited into Ondine’s Steriwave ICU pilot study

Ondine Biomedical (LON:OBI) announced the initiation of patient recruitment for an intensive care unit (ICU) pilot study at Royal Columbian Hospital (RCH) in New Westminster, British Columbia. The company states that...

March 20, 2025

Developments

USPO issues NOA to Sonnet for second IL-18 protein patent

Sonnet BioTherapeutics (NASDAQ:SONN) announced that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) for a second patent in the IL-18 variant protein field. According to...

March 19, 2025

Subscribe